Braeburn Resubmits New Drug Application for CAM2038 for Opioid Use Disorder

Corporate Breaking News

Home : Braeburn Resubmits New Drug Application for CAM2038 for Opioid Use Disorder

May 28 2018	Braeburn Resubmits New Drug Application for CAM2038 for Opioid Use Disorder
PLYMOUTH MEETING, Pa., May 28, 2018 /PRNewswire/ -- Braeburn announces the resubmission of the New Drug Application (NDA) for CAM2038, an investigational buprenorphine flexible-dose weekly and monthly depot injection for the treatment of opioid use disorder (OUD). The resubmission is in...


Source:https://www.prnewswire.com/news-releases/braeburn-resubmits-new-drug-application-for-cam2038-for-opioid-use-disorder-300655354.html

Related News
» Galaxy Derivatives Company Deploys Itiviti's Solution for Options Market Making in China » GM reconoce a Henniges Automotive por su rendimiento, calidad e innovación